Publication:
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024

Simple item page
dc.contributor.authorMerdrignac, Lore
dc.contributor.authorLaniece Delaunay, Charlotte
dc.contributor.authorVerdasca, Nuno
dc.contributor.authorVega-Piris, Lorena
dc.contributor.authorO'Donnell, Joan
dc.contributor.authorSève, Noémie
dc.contributor.authorTrobajo-Sanmartín, Camino
dc.contributor.authorBuda, Silke
dc.contributor.authorHooiveld, Mariëtte
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorTúri, Gergő
dc.contributor.authorLatorre-Margalef, Neus
dc.contributor.authorMlinarić, Ivan
dc.contributor.authorLazar, Mihaela
dc.contributor.authorMaurel, Marine
dc.contributor.authorCastrillejo, Daniel
dc.contributor.authorBennett, Charlene
dc.contributor.authorRameix-Welti, Marie-Anne
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorMeijer, Adam
dc.contributor.authorMelo, Aryse
dc.contributor.authorOroszi, Beatrix
dc.contributor.authorHagey, Tove Samuelsson
dc.contributor.authorKurečić Filipović, Sanja
dc.contributor.authorDijkstra, Frederika
dc.contributor.authorGomez, Verónica
dc.contributor.authorBacci, Sabrina
dc.contributor.authorKaczmarek, Marlena
dc.contributor.authorKissling, Esther
dc.contributor.authorVEBIS Primary Care Vaccine Effectiveness Group
dc.contributor.funderUnión Europea. European Centre for Disease Prevention and Control (ECDC)
dc.date.accessioned2025-03-11T11:36:55Z
dc.date.available2025-03-11T11:36:55Z
dc.date.issued2024-11
dc.description.abstractWe estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case-control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12-71), 23% (95% CI: -11-48) and 5% (95% CI: -92-56) among those with symptom onset 1-5, 6-11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.
dc.description.peerreviewedSí
dc.description.sponsorshipFunding for this project was received from the European Centre for Disease Prevention and Control (ECDC) implementing Framework Contract ECDC/2021/019 ‘Vaccine effectiveness, burden and impact of COVID-19 and influenza’. The funder of the study had a role in the study design, data interpretation and the review of the manuscript, but no role in data collection or data analysis. The corresponding author had full access to all the data in the study, and final responsibility for the decision to submit for publication was by consensus.
dc.format.number11
dc.format.pagee70009
dc.format.volume18
dc.identifier.citationMerdrignac L, Laniece Delaunay C, Verdasca N, Vega-Piris L, O'Donnell J, Sève N, Trobajo-Sanmartín C, Buda S, Hooiveld M, Rodrigues AP, Túri G, Latorre-Margalef N, Mlinarić I, Lazar M, Maurel M, Castrillejo D, Bennett C, Rameix-Welti MA, Martínez-Baz I, Dürrwald R, Meijer A, Melo A, Oroszi B, Hagey TS, Kurečić Filipović S, Dijkstra F, Gomez V, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024. Influenza Other Respir Viruses. 2024 Nov;18(11):e70009.
dc.identifier.doi10.1111/irv.70009
dc.identifier.e-issn1750-2659
dc.identifier.issn1750-2640
dc.identifier.journalInfluenza and other respiratory viruses
dc.identifier.pubmedID39523781
dc.identifier.urihttps://hdl.handle.net/20.500.12105/26417
dc.language.isoeng
dc.publisherWiley
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/ECDC/2021/019
dc.relation.publisherversionhttps://doi.org/10.1111/irv.70009
dc.repisalud.centroISCIII::Centro Nacional de Epidemiología (CNE)
dc.repisalud.institucionISCIII
dc.repisalud.instituteIIS::IdiSNA - Instituto de Investigación Sanitaria de Navarra (Navarra)
dc.rights.accessRightsopen access
dc.rights.licenseAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCOVID‐19
dc.subjectSARS‐CoV‐2
dc.subjectCase–control study
dc.subjectMulti‐country study
dc.subjectPrimary care
dc.subjectTest‐negative design
dc.subjectVaccine effectiveness
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshCOVID-19 Vaccines
dc.subject.meshCOVID-19
dc.subject.meshCase-Control Studies
dc.subject.meshEurope
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshPrimary Health Care
dc.subject.meshSARS-CoV-2
dc.subject.meshVaccination
dc.subject.meshVaccine Efficacy
dc.titleEffectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublicationb9db5b2d-44c4-4d09-8de8-781466b510e3
relation.isAuthorOfPublication.latestForDiscoveryb9db5b2d-44c4-4d09-8de8-781466b510e3
relation.isFunderOfPublication78e868cc-0192-448d-bcb1-98d618a7cee4
relation.isFunderOfPublication.latestForDiscovery78e868cc-0192-448d-bcb1-98d618a7cee4
relation.isPublisherOfPublicationd81e762a-95f7-4917-88a1-8004b3b8caa7
relation.isPublisherOfPublication.latestForDiscoveryd81e762a-95f7-4917-88a1-8004b3b8caa7

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
Effectiveness_XBB_1_5_Vaccines_Symptomatic_SARS-CoV-2_2024.pdf
Size:
274.49 KB
Format:
Adobe Portable Document Format
Download
Thumbnail Image
Name:
Supplementary_Effectiveness_XBB_1_5_Vaccines_Symptomatic_SARS-CoV-2_2024.pdf
Size:
540.84 KB
Format:
Adobe Portable Document Format
Download

Collections

Centro Nacional de Epidemiología (CNE)
IdiSNA - Instituto de Investigación Sanitaria de Navarra (Navarra)